Premiere Date: Friday, March 1, 2019
This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
Credit Expiration Date: Sunday, March 1, 2020
Faculty
|
Statement of Need
Residual ES in patients undergoing treatment for narcolepsy and OSA has a profound negative impact on patients' health-related quality of life (HRQoL). In order to properly treat this disorder, it is imperative that the rate of detection increases and that clinicians are educated on the efficacy of current and emerging treatment strategies that minimize the incidence of residual ES. Clinical tools such as Swiss Narcolepsy Scale (SNS) or Epworth Sleepiness Scale (ESS) should be incorporated into routine practice.
In this CME Outfitters decision-tree medical simulation, expert faculty will highlight evidence-based tools to facilitate the recognition of residual ES and provide clinicians with the latest clinical updates on the effectiveness of current and emerging therapies that promote symptom resolution and restoration of function.
Learning Objectives
At the end of this CE activity, participants should be able to:
- Increase the rate of detection of residual ES in patients with narcolepsy by incorporating clinical tools such as the Swiss Narcolepsy Scale (SNS) or Epworth Sleepiness Scale (ESS) into routine practice.
- Evaluate the efficacy of current and emerging treatment strategies that minimize the incidence of residual ES in patients with narcolepsy.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Summarize how to detect persistent excessive sleepiness in patients with OSA using clinical tools such as the Epworth Sleepiness Scale (ESS).
- Evaluate the efficacy of current and emerging treatment strategies that minimize the incidence of persistent excessive sleepiness in patients with OSA despite being optimally managed with CPAP.
Financial Support
Supported by an educational grant from Jazz Pharmaceutical, Inc.
Target Audience
Sleep specialists, pulmonologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with excessive sleepiness (ES).
Credit Information
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 0.25 contact hours (0.025 CEUs) Universal Activity Number:
Enduring: 0376-0000-18-027-H01-P
Type: Knowledge-based 
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to sub mit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Formats
Enduring material
Post-tests, credit request forms, and activity evaluation must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). this website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy/
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, have evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bogan reports that he is a consultant for Harmony Biosciences, LLC; and Jazz Pharmaceuticals Inc. He receives industry funded research from Balance; Eisai Inc.; Fisher Paykel; Fresca; Jazz Pharmaceuticals Inc.; Merck & Co., Inc. Novo Nordisk; Phillips; ResMed; Sommetrics, Inc.; Sunovion Pharmaceuticals Inc.; and Vanda Pharmaceuticals. He is on the speakers bureau for Jazz Pharmaceuticals Inc.; and Merck & Co., Inc. He is a shareholder, on the Board of Directors, Chief Medical Officer, and an employee of SleepMed, Inc. He is on the Board of Directors of First Community Corporation, SC and National Sleep Foundation.
Kashemi D. Rorie, PhD (planning committee) has nothing to disclose.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclsoures to report.
Sharon Tordoff CHCP (planning committee) has nothing to disclose.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to disclose.
Questions about this activity? Call us at 877.CME.PROS(877.263.7767).
